Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nilesh Patel

Hospitalist Baltimore, MD Medical Doctor

NPI 1710099262 CMS profile 349503

2435 W Belvedere Ave, Suite 22, Baltimore, MD 21215

Open in the dashboard

General payments

$3,387

165 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nilesh Patel of Baltimore, MD is reported in the CMS Open Payments database as having received $3,387 across 165 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Hospitalist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $307 13
2024 General $698 31
2023 General $594 30
2022 General $661 37
2021 General $578 27
2020 General $117 7
2019 General $431 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nilesh Patel
  • Hospitalist median
  • Middle half of Hospitalist
  • National median

In program year 2025, general payments to Nilesh Patel were reported at $307. Among 6,882 Hospitalist profiles paid that year, the median was $86 and the middle half received between $30 and $191.

Show as a table
Year Nilesh Patel Hospitalist median Middle half National median
2019 $431 $96 $28–$201 $163
2020 $117 $48 $19–$125 $114
2021 $578 $70 $23–$167 $132
2022 $661 $85 $27–$174 $149
2023 $594 $89 $30–$191 $160
2024 $698 $95 $29–$204 $164
2025 $307 $86 $30–$191 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $775 41 payments
  2. E.R. Squibb & Sons, L.L.C. $562 32 payments
  3. Pfizer Inc. $343 14 payments
  4. Novartis Pharmaceuticals Corporation $274 13 payments
  5. AbbVie, Inc. $244 10 payments
  6. Alexion Pharmaceuticals, Inc. $192 7 payments
  7. Merck Sharp & Dohme Corporation $125 7 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $111 5 payments
  9. Novo Nordisk Inc $105 5 payments
  10. Allergan Inc. $97 5 payments
  11. Other $560 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,387 165 payments
Products named General payments · program years 2019–2025
  1. XARELTO $775 41 payments
  2. ELIQUIS Cardiovascular $440 26 payments
  3. ELIQUIS Cardiovascular;Metabolic Disease $287 12 payments
  4. DALVANCE $264 11 payments
  5. ENTRESTO Cardiovascular $158 8 payments
  6. TEFLARO $148 7 payments
  7. ENTRESTO Cardiology/Vascular Diseases $117 5 payments
  8. XIFAXAN $111 5 payments
  9. CAMZYOS $105 5 payments
  10. Ozempic $105 5 payments
  11. Other $1,419 67 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$62,275

Medicare's payments for the services billed

Medicare patients

319

Average age 75

Services billed

880

184 women, 135 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Diabetes 55%
Chronic kidney disease 53%
Ischemic heart disease 50%
Heart failure 49%
Depression 47%
Atrial fibrillation 39%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $179
$179 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $75
$75 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $64
$64 — —
DIFICID
  • Merck Sharp & Dohme Corporation $54
$54 — —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $37
$37 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

165 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record